A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
NCT01778439
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory Solid Tumors
Interventions
DRUG:
OMP-52M51
Sponsor
OncoMed Pharmaceuticals, Inc.